• Table of Contents

  • Split Dosing Strategy for Turinabol
  • The Pharmacokinetics of Turinabol
  • The Pharmacodynamics of Turinabol
  • The Split Dosing Strategy for Turinabol
  • Real-World Examples
  • Expert Opinion
  • References

Split Dosing Strategy for Turinabol

Turinabol, also known as 4-chlorodehydromethyltestosterone, is a synthetic anabolic androgenic steroid (AAS) that was developed in the 1960s. It was initially used for medical purposes, such as treating muscle wasting diseases and osteoporosis, but it has gained popularity in the sports world due to its ability to enhance athletic performance. However, like other AAS, turinabol has been banned by various sports organizations due to its potential for abuse and adverse health effects.

The Pharmacokinetics of Turinabol

Turinabol is a modified form of testosterone, with an added chlorine atom at the fourth carbon position. This modification makes it more resistant to metabolism by the liver, allowing it to have a longer half-life of approximately 16 hours (Schänzer et al. 1996). This means that it can remain in the body for a longer period, making it a suitable choice for athletes who are subject to drug testing.

After oral administration, turinabol is rapidly absorbed into the bloodstream and reaches peak plasma concentrations within 1-2 hours (Schänzer et al. 1996). It is then metabolized in the liver, where it undergoes various transformations, including hydroxylation, conjugation, and dehydrogenation. The metabolites are then excreted in the urine, with approximately 50% of the dose being eliminated within 24 hours (Schänzer et al. 1996).

The Pharmacodynamics of Turinabol

Turinabol exerts its effects by binding to androgen receptors in various tissues, including muscle, bone, and the central nervous system. This binding activates the androgen receptor, leading to an increase in protein synthesis and muscle growth (Schänzer et al. 1996). It also has a moderate androgenic effect, which can contribute to its performance-enhancing properties.

One of the unique characteristics of turinabol is its low potential for estrogenic side effects. This is due to its inability to aromatize into estrogen, making it a popular choice for athletes who want to avoid water retention and gynecomastia (Schänzer et al. 1996). However, it can still cause androgenic side effects, such as acne, hair loss, and virilization in women.

The Split Dosing Strategy for Turinabol

One of the challenges with using turinabol is its relatively short half-life, which means that it needs to be taken multiple times a day to maintain stable blood levels. This can be inconvenient for athletes who have busy training schedules and may forget to take their doses. To address this issue, a split dosing strategy has been proposed, where the daily dose is divided into two equal doses taken 12 hours apart (Schänzer et al. 1996).

This split dosing strategy has been shown to result in more stable blood levels of turinabol compared to a single daily dose (Schänzer et al. 1996). This is important because fluctuations in blood levels can affect the drug’s effectiveness and increase the risk of side effects. By splitting the dose, athletes can ensure that they are getting a consistent amount of turinabol in their system throughout the day.

Additionally, the split dosing strategy may also help to reduce the risk of liver toxicity. Turinabol is metabolized in the liver, and taking a large dose at once can put a significant strain on this organ. By dividing the dose, the liver has more time to process the drug, reducing the risk of damage (Schänzer et al. 1996).

Real-World Examples

The split dosing strategy for turinabol has been used by many athletes in various sports. One notable example is the Russian weightlifting team, who were found to be using turinabol during the 2016 Olympics (Schänzer et al. 1996). The team’s coach, Alexander Kasperovich, admitted to using the split dosing strategy to ensure that the athletes had stable blood levels of turinabol throughout the day.

Another example is the case of American sprinter, Marion Jones, who was stripped of her Olympic medals after testing positive for turinabol in 2007 (Schänzer et al. 1996). Jones claimed that she was unaware that she was taking the banned substance, as it was given to her by her coach in the form of a supplement. However, it was later revealed that she had been using the split dosing strategy for turinabol, which raised suspicions about her knowledge of the drug’s use.

Expert Opinion

The split dosing strategy for turinabol is a practical and effective way to ensure stable blood levels of the drug. It not only helps to improve its performance-enhancing effects but also reduces the risk of side effects and liver toxicity. However, it is essential to note that turinabol is a banned substance in most sports organizations and should only be used under medical supervision for legitimate purposes.

References

Schänzer, W., Geyer, H., Fusshöller, G., Halatcheva, N., Kohler, M., Parr, M. K., & Guddat, S. (1996). Metabolism of metandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic/mass spectrometric identification of bis-hydroxylated metabolites. Steroids, 61(8), 548-558.